Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any supplement regimen or making changes to your health routine. The information presented here is based on published research but should not replace professional medical guidance.
NAD+ (nicotinamide adenine dinucleotide) is one of the most-discussed molecules in longevity research, and for good reason — it’s a coenzyme required for hundreds of cellular reactions, from energy production to DNA repair. But the “NAD+ declines with age” claim gets repeated so often that the actual mechanism behind it rarely gets explained. Here’s what’s actually going on at the cellular level, and what the research does and doesn’t support.
What NAD+ Actually Does
NAD+ is a coenzyme — a helper molecule required for enzymes to do their job — involved in over 500 metabolic reactions. Its two biggest roles for longevity purposes are:
- Energy metabolism: NAD+ (and its reduced form, NADH) shuttles electrons through the mitochondrial electron transport chain, the process that generates the majority of your cellular energy (ATP).
- DNA repair and cellular signalling: NAD+ is consumed as a substrate — not just used as a helper — by enzyme families including sirtuins (which regulate gene expression and metabolic health) and PARPs (which repair damaged DNA).
This dual role — energy production and being consumed by repair enzymes — is central to why NAD+ decline matters so much. It isn’t simply “used up” the way a battery drains; specific enzymes actively consume it, and that consumption increases with age.
How Much Does NAD+ Actually Decline?
Multiple studies across tissue types have documented substantial NAD+ decline with age — commonly cited estimates suggest NAD+ levels fall by approximately 50% between the ages of 20 and 60, though the exact magnitude varies by tissue type and measurement method. The decline appears to accelerate rather than proceed linearly, with some research suggesting a more pronounced drop from midlife onward.
Why NAD+ Declines: Three Converging Mechanisms
NAD+ decline isn’t caused by one single process — it’s the net result of declining production and increasing consumption happening at the same time.
1. Declining Biosynthesis
Your body makes NAD+ primarily through the “salvage pathway,” recycling nicotinamide (a breakdown product of NAD+ itself) back into new NAD+ via a multi-step process. Expression of the enzymes that run this pathway, including NAMPT (the rate-limiting enzyme), has been shown to decline with age in multiple tissue types, meaning your cells become less efficient at replenishing NAD+ even before consumption is factored in.
2. Increasing Consumption by Repair Enzymes
As cells accumulate DNA damage over a lifetime, PARP enzymes — which repair that damage — consume more NAD+ to do their job. Chronic low-grade inflammation, which increases with age (sometimes called “inflammaging”), also drives up activity of NAD+-consuming enzymes in immune cells. The net effect is that ageing tissue is both making less NAD+ and burning through more of what it does make.
3. The Pseudohypoxic State
Perhaps the most elegant mechanistic explanation comes from a landmark study showing that declining NAD+ disrupts communication between the nucleus and mitochondria, inducing a cellular state that mimics hypoxia (oxygen deprivation) even when oxygen is plentiful. This “pseudohypoxic state” impairs mitochondrial function in a way that compounds the original NAD+ shortfall — a feedback loop where declining NAD+ causes mitochondrial dysfunction, which further stresses cellular energy metabolism.[1]
The Feedback Loop, Simplified
Less NAD+ production + more NAD+ consumption + mitochondrial dysfunction from the resulting pseudohypoxic state = a self-reinforcing cycle. This is part of why NAD+ decline is considered a contributing driver of multiple hallmarks of ageing rather than an isolated, standalone process.[6]
Why This Matters for Ageing
Because NAD+ sits at the intersection of energy metabolism, DNA repair, and sirtuin-mediated gene regulation, its decline has been mechanistically linked to reduced mitochondrial function, impaired DNA damage response, and metabolic dysfunction — all recognised hallmarks of the ageing process.[6] This is the biological rationale behind the interest in NAD+ precursor supplementation (NMN and NR), which aims to support biosynthesis rather than address consumption directly.
Can You Reverse the Decline?
Human trials of NAD+ precursors have shown that supplementation can meaningfully raise blood and tissue NAD+ levels. A trial of nicotinamide riboside established that oral supplementation reliably increases NAD+ metabolism in humans.[2] Foundational animal work demonstrated that long-term NMN administration mitigates several age-associated physiological declines in mice, including improvements in energy metabolism, insulin sensitivity, and mitochondrial function.[3] In humans, NMN supplementation has been shown to improve muscle insulin sensitivity in a trial of prediabetic women.[4]
What hasn’t been established is whether raising NAD+ levels back toward youthful ranges translates into slower ageing or longer healthy lifespan in humans — the trials to date measure biomarkers and specific functional outcomes (like insulin sensitivity), not overall ageing rate or lifespan. I cover the practical supplementation question, including dosing and NMN-vs-NR comparisons, in my NMN review, nicotinamide riboside review, and NMN vs NR comparison.
Frequently Asked Questions
At what age does NAD+ start declining?
Research suggests measurable NAD+ decline begins as early as the 30s, with the most commonly cited figure being roughly a 50% reduction between age 20 and age 60. The exact trajectory varies by tissue and measurement method, and the decline may accelerate in later decades rather than being perfectly linear.
Is NAD+ decline caused by one specific thing?
No — it’s the combined result of declining biosynthesis (production slows as key enzymes become less active), increased consumption (DNA repair and inflammation-related enzymes consume more NAD+ with age), and a resulting mitochondrial dysfunction that compounds the original shortfall.
Can exercise or diet slow NAD+ decline?
Exercise is one of the most consistently supported non-supplement approaches to supporting healthy NAD+ metabolism and mitochondrial function generally, though it hasn’t been shown to fully prevent age-related decline. Chronic caloric excess and metabolic dysfunction are associated with lower NAD+ status, which is part of the rationale behind interest in caloric restriction and time-restricted eating in longevity research.
Does taking NMN or NR actually reverse NAD+ decline?
Human trials show both compounds reliably raise NAD+ levels and related biomarkers. Whether this “reverses ageing” in a meaningful clinical sense is a separate, unproven question — the trials to date show biomarker and specific functional improvements (such as insulin sensitivity), not a demonstrated slowing of the overall ageing process.
What is the “pseudohypoxic state” and why does it matter?
It’s a cellular condition, identified in a landmark 2013 study, where declining NAD+ disrupts communication between the nucleus and mitochondria, causing cells to behave as if oxygen-deprived even when oxygen is available.[1] It matters because it shows NAD+ decline doesn’t just reduce energy availability — it actively impairs mitochondrial function through a distinct signalling mechanism, compounding the problem.
Citations
- Gomes AP, Price NL, Ling AJ, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638. PMID: 24360282
- Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PMID: 27721479
- Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. PMID: 28068668
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33378629
- Cantó C, Houtkooper RH, Pirinen E, et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838-847. PMID: 22682224
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. PMID: 36599349
Last reviewed: 18 Sep 2026 by Steve Butler, Health Writer & Longevity Researcher